ARCHIVES

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

NCI To Test 5,000 DC-Area Jews To Determine Risk Of BRCA 1 Mutation

October 6, 1995

In Brief: Bristol To Drop Angiostatin; Protein Fails To Meet Criteria For Development, Firm Says

February 12, 1999

From One Competitive Market to Another: UC San Diego Stakes A Claim in Las Vegas

January 27, 2012

NCI To Lose 19% of Workforce Over Six Years, Broder Says

November 4, 1994

Cancer Control Grows Up Fast As It Moves To Meet Mandate, Take Over Big Part Of NCI Budget

March 15, 1974

Senate Bill Includes $10 Billion for NIH

February 6, 2009